NorthWest Biotherapeutics Inc (NWBO)

[abc1212]

From the 38th Annual J.P. Morgan Healthcare Conference website

More Drugs on the Market

https://www.jpmorgan.com/global/research/future-of-healthcare

This move from price-driven to innovation-driven growth is also being supported by an uptick in Food and Drug Administration (FDA) product approvals. Drugmakers spend billions of dollars every year on research and development (R&D) of new drugs, with many of those drugs failing to pass rigorous FDA tests to get to market.
For much of the last decade, the FDA approved around 20 to 25 new products per year according to J.P. Morgan data. In the last two years, between 40 and 50 new drugs have been approved annually and approvals are expected to stay around this level for the foreseeable future.
Breakthroughs in key areas such as oncology and immunology and gene therapy in the biotech industry are also opening up previously untapped markets for drugmakers. “We are witnessing scientific breakthroughs in areas such as immuno-oncology, where the body’s immune system is used to fight off cancer.
That has probably been the biggest breakthrough in my sector in the last 40 or 50 years and is dramatically able to improve outcomes for patients who didn’t have treatment alternatives in the past,” Schott said.

Chris Schott Senior Analyst,
U.S. Major and Specialty Pharmaceuticals
J.P. Morgan